Jim Cramer on Regeneron: “There Could Be Some More Downgrades”

Finally, there’s Regeneron, which got blasted by a mediocre effect connected a metastatic melanoma crab trial. I, on with galore others, thought that this proceedings would succeed. You can’t bargain a cause banal that falls that overmuch connected the archetypal time of the decline. Most analysts look to person keyed connected this cause to urge the stock. It’s damaged. There could beryllium immoderate much downgrades.

A banal marketplace chart. Photo by Arturo A connected Pexels Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for oculus conditions, immune disorders, cancer, cardiovascular issues, infections, and uncommon diseases. A caller asked for Cramer’s thoughts connected the institution during the April 9 episode. The Mad Money big responded:

I deliberation Regeneron, I deliberation Leonard Schleifer’s doing an unbelievable job. I deliberation the stock’s breaking retired here, I truly do. I mean, I looked astatine it for the Charitable Trust, that and Amgen, we bought different stock, but those are the 2 I truly like.

While we admit the imaginable of REGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock. READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years  Disclosure: None. Follow Insider Monkey connected Google News.